Physician profile
Jesus Mayor
NPI 1689727257
$720.40
in general payments reported to CMS, 2019-2025
15 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.84 · 2020: $96.98 · 2021: $152 · 2022: $102 · 2023: $68.55 · 2024: $104 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $169.87 | 2021-2025 | Bexsero, Rotarix, Pediarix |
| Pfizer INC. | $133.67 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $120.15 | 2020-2025 | Nuzyra |
| Amgen INC. | $63.94 | 2024-2025 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.59 | 2021-2023 | Xifaxan |
| Exact Sciences Corporation | $44.15 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $39.62 | 2025 | Horizant, Edarbi |
| Phadia US INC. | $21.95 | 2024 | Immunocap |
| Genentech USA, INC. | $17.35 | 2019 | |
| Lilly USA, LLC | $16.63 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $15.49 | 2019 | |
| Astellas Pharma US INC | $14.99 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Mayor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.